<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-136612</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Combined hamartoma of the retina and retinal pigment epithelium. Anti-VEGF treatment of the associated choroidal neovascular membranes</dc:title>
<dc:description xml:lang="en">Case report: A 58 year-old female was diagnosed with a juxtapapillary combined hamartoma of the retina and retinal pigment epithelium (CHR-RPE) in her left eye 14 years ago. Her visual acuity in that eye was 20/20. Recently, she came to our department with a sudden visual loss and metamorphopsis in her left eye. After performing funduscopy, angiography and OCT, she was diagnosed with choroidal neovascular membrane (CNVM) at lesion border, and started on antiangiogenic therapy. Discussion: CHR-RPE, despite being a benign condition, may become complicated with severe visual impairment. Antiangiogenic therapy provides a good alternative to photodynamic therapy or laser photocoagulation for treatment of CNVM, avoiding adding iatrogenesis from these treatment to the complications associated with this pathology (AU)</dc:description>
<dc:creator>Nievas,  T</dc:creator>
<dc:creator>Echevarría, L</dc:creator>
<dc:creator>Villena, O</dc:creator>
<dc:creator>Bellido, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Paciente de 58 años diagnosticada de hamartoma combinado del epitelio pigmentario retiniano (CHRRPE) yuxtapapilar unilateral en ojo izquierdo hace 14 años, con máxima agudeza visual. Acude con pérdida de visión brusca y metamorfopsias en dicho ojo. Tras funduscopia, angiografía y OCT se diagnostica membrana neovascular coroidea (MNVC) en el borde de la lesión, y se inicia terapia antiangiogénica. Discusión: El CHRRPE, aunque benigno, puede complicarse produciendo gran deterioro visual. Los antiangiogénicos son buena opción frente a terapia fotodinámica o a fotocoagulación láser para tratar las MNVC, evitando sumar la iatrogenia del tratamiento a complicaciones propias de la patología (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;90(2): 87-93, feb. 2015. ilus</dc:source>
<dc:identifier>ibc-136612</dc:identifier>
<dc:title xml:lang="es">Hamartoma combinado de retina y del epitelio pigmentario. Abordaje mediante terapia anti-VEGF de membranas neovasculares asociadas</dc:title>
<dc:subject>^d12578^s22005</dc:subject>
<dc:subject>^d33272^s22044</dc:subject>
<dc:subject>^d6376^s22053</dc:subject>
<dc:subject>^d33272^s22042</dc:subject>
<dc:subject>^d33272^s22031</dc:subject>
<dc:subject>^d6376^s22012</dc:subject>
<dc:subject>^d9562^s22016</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23106^s22000</dc:subject>
<dc:subject>^d9562^s22036</dc:subject>
<dc:subject>^d6376^s22044</dc:subject>
<dc:subject>^d6376^s22016</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d33272^s22005</dc:subject>
<dc:subject>^d23106</dc:subject>
<dc:subject>^d12578^s22010</dc:subject>
<dc:type>article</dc:type>
<dc:date>201502</dc:date>
</metadata>
</record>
</ibecs-document>
